Study S000397

A Randomized, Double-blind, Placebo-controlled Phase 3 Study Evaluating the Efficacy and Safety of IBI362 9 mg in Chinese Participants With Obesity (GLORY-2)

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06164873
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: QUADRUPLE
Status: UNKNOWN
Enrollment: 462
Start: 2023-12-27
Primary completion: 2025-06-27
Lead sponsor: Innovent Biologics (Suzhou) Co. Ltd.
Conditions: Obesity
Interventions: DRUG:IBI362; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percent Change from Baseline in Body Weight [Week 60]
Proportion of Participants who Achieve ≥5% Body Weight Reduction [Week 60]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0010279	Treatment With 9-mg Mazdutide for Weight Reduction in Chinese Adults With Obesity: The GLORY-2 Randomized Clinical Trial. Gao L, JAMA	2026	Randomized trial	PMID 42251595 DOI	cites ClinicalTrials.gov:NCT06164873; registry reference DERIVED:42251595
R0037205	1225-OR: Efficacy and Safety of Mazdutide 9 mg in Chinese Adults with Obesity: Results from the Phase 3 GLORY-2 Trial LINONG JI, Diabetes	2026	Randomized trial	DOI	cites ClinicalTrials.gov:NCT06164873